

## Supporting information – Foster, et al.

**Supplementary Table 1: Rimonabant EC<sub>50</sub> values in the THLE cell lines**

THLE cell line	Mean (μM)	SD	n
1A2	8.5	2.8	4
2C9	4.5**	0.6	6
2C19	6.0	1.6	3
2D6	9.0	1.7	3
3A4	1.3***	0.2	7
Null <sup>1</sup>	8.4	2.0	8


<sup>1</sup> where the EC<sub>50</sub> value exceeded the top concentration tested the EC<sub>50</sub> value was set to the top concentration (10 μM). \*\* P<0.01; \*\*\* p<0.001 statistically significant difference from the THLE-Null EC<sub>50</sub>; paired t-test

**Supplementary Table 2: The effect of Ritonavir on the Rimonabant EC<sub>50</sub> values in the THLE-3A4 and Null cell lines**

THLE cell line	Ritonavir (0.3 μM)	Mean (μM)	SD	n
3A4	-	1.3	0.2	4
Null1	-	8.4	2.0	4
3A4	+	4.3*	1.1	4
Null <sup>1</sup>	+	8.4	1.5	4


<sup>1</sup> where the EC<sub>50</sub> value exceeded the top concentration tested the EC<sub>50</sub> value was set to the top concentration (10 μM). \* p<0.05 statistically significant difference from EC<sub>50</sub> in THLE-3A4 cells in absence of inhibitor; paired t-test

**Supplementary Figure 1 LC-MS analysis of supernatants from THLE-3A4 cells incubated with [ $^{14}\text{C}$ ]-rimonabant**



Extracted ion chromatograms for (A) amide cleavage product 6 ( $\text{MH}^+$  380.9959), (B) +32 ( $\text{MH}^+$  495.0752), (C) +16 ( $\text{MH}^+$  479.0802) and (D) -2 Da ( $\text{M}^+$  461.0697) metabolites.

## Supplementary Figure 2 Toxicity of NAP in the THLE cells




Evaluation of the toxicity of NAP in the THLE-1A2, 2C9, 2C19, 2D6, 3A4 and Null cells.

The cells were exposed to 0 – 300 µM NAP for 24 hours; ▼ 1A2, ◇ 2C9, ■ 2C19, ● 2D6, △

3A4, x Null. Data are mean ± S.D. from 3 experiments each performed in triplicate.

## Supplementary Figure 3 Intracellular NAP determination



Evaluation of the intracellular penetration of NAP. Twenty four hours post-dosing with 300 µM NAP the medium was removed, the cells washed with 40 mL HBSS-/-, scraped into 1 mL de-ionised water and then lysed by sonication prior to analysis by LCMS. Data are from

duplicate injections ((a) and (b)). THLE-Null lysate samples were spiked with 5  $\mu$ L 300  $\mu$ M NAP diluted 20 fold (0.75  $\mu$ M final concentration) to confirm the identification of the peak and to give an approximate concentration in the initial samples in the absence of a standard curve (area increased by  $\sim 2$  fold).

**Supplementary Figure 4 Structure of Ritonavir**

